Combination therapy of diseases: General concepts

Antiepileptic Drugs: Combination Therapy and Interactions

Volumn , Issue , 2005, Pages 3-15

  Mason, Emma ^a   Routledge, Philip A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58349122519     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545023.003     Document Type: Chapter

References (57)

1. Bartlett EE. Polypharmacy versus hypnosis in surgical patients. Pac Med Surg1966; 74: 109–112.
2. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med2000; 160: 2129–2134.
3. Chambers HF, Sande MA. Antimicrobial agents: general considerations. In Goodman and Oilman’s The Pharmacological basis of Therapeutics, 9th edn. USA: McGraw Hill, 1996.
4. DeFronzo RA, Goodman A and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New Engl J Med1995; 335: 541–549.
5. Deisenhammer E, Sommer R. Blood level of antiepileptic drugs and therapeutic effect in monoand polytherapy. Nervenarzt1978; 49: 674–677.
6. Duncan LJ, Clarke BF, Munro JF. The treatment of diabetes mellitus with oral hypoglycaemic drugs. Curr Med Drug 1965; 5: 23–32.
7. Encyclopaedia Britannica on CD ROM, Multimedia Edition. 1999.
8. Fincke BG, Miller DR, Spiro A III. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med1998; 13: 182–185.
9. Freestone DS. Formulation and therapeutic efficacy of drugs used in clinical trials. Lancet1969; 2: 98–99.
10. Frishman WH. Mibefradil: A new selective T-channel calcium antagonist for hypertension and angina pectoris. J. Cardiovasc Pharmacol Ther1997; 2: 321–330.
11. Gerich JE. Oral hypoglycaemic agents. New Engl J Med1989; 321: 1231–1235.
12. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med1991; 114: 257–263.
13. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug–drug interactions in a Medicaid population. Pharmacotherapy1998; 18: 1112–1120.
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998; 351: 1755–1762.
15. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care1994; 17: 1100–1109.
16. Hogerzeil HV, Bimo, Ross-Degnan D, Laing RO, et al. Field tests for rational drug use in twelve developing countries. Lancet1993; 342: 1408–1410.
17. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. New Engl J Med2001; 344: 1132–1138.
18. Hudson RP. Polypharmacy in twentieth century America. Clin Pharmacol Ther1968; 9: 2–10.
19. Jallon P. Monotherapy and polytherapy use of anti-epileptic drugs. Development of views. Rev Neurol (Paris)1997; 153(Suppl. 1): 829–833.
20. Kalviainen R, Keranen T, Riekkinen Sr PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs1993; 46: 1009–1024.
21. Lambie DG, Johnson RH, Stanaway L. Prescribing patterns for epilepsy. New Zeal Med J1981; 93: 15–19.
22. Lambie DG, Stanaway L, Johnson RH. Factors which influence the effectiveness of treatment of epilepsy. Aust NZ J Med1986; 16: 779–784.
23. Lind J. A Treatise of the Scurvy. In three parts. Containing an inquiry into the nature, causes and cure, of that disease; together with a critical and chronological view of what has been published on the subject. Edinburgh: Printed by Sands, Murray and Cochran for A. Kincaid and A. Donaldson, 1753.
24. Lyons AS, Petrucelli RJ. Medicine: An Illustrated History. New York: Harry N Abrams, Inc., 1987.
25. Mancia G, et al. Guidelines for the treatment of hypertension: a commentary. Curr Ther Res1996; 57: 3–15.
26. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens1995; 8: 189–192.
27. May FE, Fuller S, Stewart RB. Drug use and adverse drug reactions prior to and during hospitalization. J Amer Pharm Assoc1977; 17: 560–563.
28. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J1948; 2: 769–782.
29. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalycilic acid. Br Med J1950; 2: 1073–1083.
30. Muggia FM, Von Hoff DD. Malignant diseases. In Avery’s Drug Treatment, 4th edn. T. M. Speight, N. H. G. Holford, eds. Auckland: Adis International, 1997.
31. Nies AS, Spielberg SP. Principles of therapeutics. In Goodman and Oilman’s The Pharmacological Basis of Therapeutics, 9th edn. USA: McGraw Hill, 1996.
32. Nilsson L, Bergman U, Diwan V, et al. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia2001; 42: 667–673.
33. Nobili A, Tettamanti M, Frattura L, et al. Drug use by the elderly in Italy. Ann Pharmacother1997; 31: 416–422.
34. O’Meara NM, Shapiro ET, van Cauter E, et al. Effect of glyburide on b-cell responsiveness to glucose in non-insulin-dependent diabetes mellitus. Am J Med1990; 89(Suppl. 2A): 11S–16S.
35. Online Medical Dictionary. http: //www. medic8. com/MedicalDictionary. htm
36. Opie LH. Principles of combination therapy for hypertension. What we learn from HOT and other studies – a personal point of view. Cardiovasc Drug Ther1998; 12: 425–429.
37. Pellock JM. Antiepileptic drug therapy in the United States: a review of clinical studies and unmet needs. Neurology1995; 45: 817–824.
38. Pierce RV. The Peoples Common Sense Medical Adviser in Plain English or Medicine Simplified, 26th edn. Buffalo, NY: World’s Dispensary Printing Office and Bindery, 1891.
39. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med1991; 114: 735–740.
40. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet1998; 351: 1829–1830.
41. Reus VI. Rational polypharmacy in the treatment of mood disorders. Ann Clin Psychiatry1993; 5: 91–100.
42. Richens A. Rational polypharmacy. Seizure1995; 4: 211–214.
43. Routledge P. 150 years of pharmacovigilance. Lancet1998a; 351: 1200–1201.
44. Routledge P. In Detection of New Adverse Reactions, 4th edn. M. D. B. Stephens, J. C. C. Talbot, P. A. Routledge, eds. London: Macmillan Reference Ltd., 1998b.
45. Seymour RM, Routledge PA. Important drug–drug interactions in the elderly. Drug Ageing1998; 6: 485–494.
46. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med1993; 153(14): 1665–1670.
47. Stephens M. In Detection of New Adverse Reactions, 4th edn. M. D. B. Stephens, J. C. C. Talbot, P. A. Routledge, eds. London: Macmillan Reference Ltd., 1998.
48. Stewart RB, Cooper JW. Polypharmacy in the aged. Practical solutions. Drug Aging1994; 4: 449–461.
49. Teng Liaw ST. Drug interactions among the elderly. Aust Fam Phys 1997; 26: 355–357.
50. The New Shorter Oxford Dictionary. L. Brown, ed. Oxford: Oxford University Press, 2001.
51. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. Br Med J1970; 4: 271–273.
52. Waksman SA (ed.). Streptomycin: Nature, and Practical Applications. Baltimore: The Williams & Wilkins Co., 1949.
53. Wandel C, Kim RB, Guengerich FP, et al. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos2000; 28: 895–898.
54. Watabe T. Strategic proposals for predicting drug–drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs. J Toxicol Sci1996; 21: 299–300.
55. Wilson A. Diseases of the brain and nervous system. In The Modern Physician. London: Caxton Publishing Company, 1912.
56. Wilson WR, Geraci IE, Wilkowske CJ, et al. Short-term intramuscular therapy with procaine penicillin plus streptomycin for infective endocarditis due to viridans streptococci. Circulation1978; 57: 1158–1161.
57. Wolkowitz OM. Rational polypharmacy in schizophrenia. Ann Clin Psychiat1993; 5: 79–90.